These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 30324350)
41. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Tang W; Fan W; Lau J; Deng L; Shen Z; Chen X Chem Soc Rev; 2019 Jun; 48(11):2967-3014. PubMed ID: 31089607 [TBL] [Abstract][Full Text] [Related]
42. Recent Trends in Nanocarrier-Based Drug Delivery System for Prostate Cancer. Kumar A; Lunawat AK; Kumar A; Sharma T; Islam MM; Kahlon MS; Mukherjee D; Narang RK; Raikwar S AAPS PharmSciTech; 2024 Mar; 25(3):55. PubMed ID: 38448649 [TBL] [Abstract][Full Text] [Related]
43. Cancer Nanotechnology in Medicine: A Promising Approach for Cancer Detection and Diagnosis. Stephen BJ; Suchanti S; Mishra R; Singh A Crit Rev Ther Drug Carrier Syst; 2020; 37(4):375-405. PubMed ID: 32865930 [TBL] [Abstract][Full Text] [Related]
44. Nanoparticle therapeutics for prostate cancer treatment. Sanna V; Sechi M Maturitas; 2012 Sep; 73(1):27-32. PubMed ID: 22341739 [TBL] [Abstract][Full Text] [Related]
45. Therapeutic efficacy of nanomedicines for prostate cancer: An update. Lakshmanan VK Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723 [TBL] [Abstract][Full Text] [Related]
46. Multiparametric MRI in detection and staging of prostate cancer. Boesen L Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066 [TBL] [Abstract][Full Text] [Related]
47. Perspectives and potential applications of nanomedicine in breast and prostate cancer. Liu Y; Solomon M; Achilefu S Med Res Rev; 2013 Jan; 33(1):3-32. PubMed ID: 23239045 [TBL] [Abstract][Full Text] [Related]
48. Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells. Sanna V; Pintus G; Roggio AM; Punzoni S; Posadino AM; Arca A; Marceddu S; Bandiera P; Uzzau S; Sechi M J Med Chem; 2011 Mar; 54(5):1321-32. PubMed ID: 21306166 [TBL] [Abstract][Full Text] [Related]
49. Theranostic applications of carbon nanomaterials in cancer: Focus on imaging and cargo delivery. Chen D; Dougherty CA; Zhu K; Hong H J Control Release; 2015 Jul; 210():230-45. PubMed ID: 25910580 [TBL] [Abstract][Full Text] [Related]
50. TRAIL and microRNAs in the treatment of prostate cancer: therapeutic potential and role of nanotechnology. Farooqi AA; De Rosa G Appl Microbiol Biotechnol; 2013 Oct; 97(20):8849-57. PubMed ID: 24037407 [TBL] [Abstract][Full Text] [Related]
51. Imaging of Prostate Cancer Using Singh A; Kulkarni HR; Baum RP PET Clin; 2017 Apr; 12(2):193-203. PubMed ID: 28267453 [TBL] [Abstract][Full Text] [Related]
52. Magnetic nanoformulations for prostate cancer. Chowdhury P; Roberts AM; Khan S; Hafeez BB; Chauhan SC; Jaggi M; Yallapu MM Drug Discov Today; 2017 Aug; 22(8):1233-1241. PubMed ID: 28526660 [TBL] [Abstract][Full Text] [Related]
53. Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer. Rhoda K; Choonara YE; Kumar P; Bijukumar D; du Toit LC; Pillay V Expert Opin Drug Deliv; 2015 Apr; 12(4):613-34. PubMed ID: 25300775 [TBL] [Abstract][Full Text] [Related]
54. Nanoparticles in cancer chemotherapy. Banerjee D; Sengupta S Prog Mol Biol Transl Sci; 2011; 104():489-507. PubMed ID: 22093227 [TBL] [Abstract][Full Text] [Related]
56. Systematic review: the applications of nanotechnology in gastroenterology. Brakmane G; Winslet M; Seifalian AM Aliment Pharmacol Ther; 2012 Aug; 36(3):213-21. PubMed ID: 22686286 [TBL] [Abstract][Full Text] [Related]
57. HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy. Lin TY; Guo W; Long Q; Ma A; Liu Q; Zhang H; Huang Y; Chandrasekaran S; Pan C; Lam KS; Li Y Theranostics; 2016; 6(9):1324-35. PubMed ID: 27375782 [TBL] [Abstract][Full Text] [Related]
58. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans. Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990 [TBL] [Abstract][Full Text] [Related]
59. Contrast specific imaging in the detection and localization of prostate cancer. Wijkstra H; Wink MH; de la Rosette JJ World J Urol; 2004 Nov; 22(5):346-50. PubMed ID: 15480696 [TBL] [Abstract][Full Text] [Related]